These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 25595389)
21. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. Bal SM; Slütter B; van Riet E; Kruithof AC; Ding Z; Kersten GF; Jiskoot W; Bouwstra JA J Control Release; 2010 Mar; 142(3):374-83. PubMed ID: 19932723 [TBL] [Abstract][Full Text] [Related]
22. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery. Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762 [TBL] [Abstract][Full Text] [Related]
23. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572 [TBL] [Abstract][Full Text] [Related]
24. pH Sensitive phosphorylated chitosan hydrogel as vaccine delivery system for intramuscular immunization. Wei J; Xue W; Yu X; Qiu X; Liu Z J Biomater Appl; 2017 May; 31(10):1358-1369. PubMed ID: 28387574 [TBL] [Abstract][Full Text] [Related]
25. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation. Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys. Torikai Y; Sasaki Y; Sasaki K; Kyuno A; Haruta S; Tanimoto A J Pharm Sci; 2021 May; 110(5):2038-2046. PubMed ID: 33278410 [TBL] [Abstract][Full Text] [Related]
31. Dry powder nasal vaccines as an alternative to needle-based delivery. Hickey AJ; Garmise RJ Crit Rev Ther Drug Carrier Syst; 2009; 26(1):1-27. PubMed ID: 19496746 [TBL] [Abstract][Full Text] [Related]
33. Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery. Li X; Guo Q; Zheng X; Kong X; Shi S; Chen L; Zhao X; Wei Y; Qian Z Drug Deliv; 2009 Apr; 16(3):160-6. PubMed ID: 19514976 [TBL] [Abstract][Full Text] [Related]
34. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. Boonyo W; Junginger HE; Waranuch N; Polnok A; Pitaksuteepong T J Control Release; 2007 Aug; 121(3):168-75. PubMed ID: 17644205 [TBL] [Abstract][Full Text] [Related]
35. Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization. Liu Q; Zhang C; Zheng X; Shao X; Zhang X; Zhang Q; Jiang X Vaccine; 2014 May; 32(22):2582-90. PubMed ID: 24681230 [TBL] [Abstract][Full Text] [Related]
36. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation. Bal SM; Slütter B; Jiskoot W; Bouwstra JA Vaccine; 2011 May; 29(23):4025-32. PubMed ID: 21443959 [TBL] [Abstract][Full Text] [Related]
37. Encapsulation of antigen-loaded silica nanoparticles into microparticles for intradermal powder injection. Deng Y; Mathaes R; Winter G; Engert J Eur J Pharm Sci; 2014 Oct; 63():154-66. PubMed ID: 25042055 [TBL] [Abstract][Full Text] [Related]
38. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455 [TBL] [Abstract][Full Text] [Related]
39. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. Hagenaars N; Mania M; de Jong P; Que I; Nieuwland R; Slütter B; Glansbeek H; Heldens J; van den Bosch H; Löwik C; Kaijzel E; Mastrobattista E; Jiskoot W J Control Release; 2010 May; 144(1):17-24. PubMed ID: 20100528 [TBL] [Abstract][Full Text] [Related]
40. Tailoring nanostructured lipid carriers for the delivery of protein antigens: Physicochemical properties versus immunogenicity studies. Courant T; Bayon E; Reynaud-Dougier HL; Villiers C; Menneteau M; Marche PN; Navarro FP Biomaterials; 2017 Aug; 136():29-42. PubMed ID: 28511142 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]